These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30265243)

  • 1. Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults.
    Hiransuthikul A; Thammajaruk N; Techatanawat I; Karachot B; Chuasuwan B; Manamuti C; Duereh M; Sawpitiporn M; Sophonphan J; Gatechompol S; Avihingsanon A; Bowonwattanuwong C; Ruxrungtham K;
    Antivir Ther; 2018; 23(8):699-703. PubMed ID: 30265243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients.
    Punyawudho B; Thammajaruk N; Ruxrungtham K; Avihingsanon A
    Int J Antimicrob Agents; 2017 Mar; 49(3):327-332. PubMed ID: 28109702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.
    Ramautarsing RA; van der Lugt J; Gorowara M; Sophonphan J; Ananworanich J; Lange JM; Burger DM; Phanuphak P; Ruxthungtham K; Avihingsanon A
    Antivir Ther; 2013; 18(2):249-52. PubMed ID: 22908131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
    Sevinsky H; Zaru L; Wang R; Xu X; Pikora C; Correll TA; Eley T
    Pediatr Infect Dis J; 2018 Jun; 37(6):e157-e165. PubMed ID: 29206748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.
    Bunupuradah T; Kiertiburanakul S; Avihingsanon A; Chetchotisakd P; Techapornroong M; Leerattanapetch N; Kantipong P; Bowonwatanuwong C; Banchongkit S; Klinbuayaem V; Mekviwattanawong S; Nimitvilai S; Jirajariyavej S; Prasithsirikul W; Munsakul W; Bhakeecheep S; Chaivooth S; Phanuphak P; Cooper DA; Apornpong T; Kerr SJ; Emery S; Ruxrungtham K;
    Lancet HIV; 2016 Aug; 3(8):e343-e350. PubMed ID: 27470026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
    Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years.
    Strehlau R; Donati AP; Arce PM; Lissens J; Yang R; Biguenet S; Cambilargiu D; Hardy H; Correll T
    J Int AIDS Soc; 2015; 18(1):19467. PubMed ID: 26066346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.
    Gallant J; Moyle G; Berenguer J; Shalit P; Cao H; Liu YP; Myers J; Rosenblatt L; Yang L; Szwarcberg J
    Curr HIV Res; 2017; 15(3):216-224. PubMed ID: 27774892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 Study.
    Cotton MF; Liberty A; Torres-Escobar I; Gonzalez-Tome MI; Lissens J; Zaru L; Klauck I; Cambilargiu D; Pikora C; Correll TA
    Pediatr Infect Dis J; 2018 Jun; 37(6):e149-e156. PubMed ID: 29206747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
    Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
    Harris M; Ganase B; Watson B; Hull MW; Guillemi SA; Zhang W; Saeedi R; Harrigan PR
    HIV Clin Trials; 2017 Jan; 18(1):39-47. PubMed ID: 28067119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
    Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
    HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
    Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
    AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
    Bunupuradah T; Techasaensiri C; Keadpudsa S; Thammajaruk N; Srimuan A; Sahakijpicharn T; Prasitsuebsai W; Ananworanich J; Puthanakit T;
    Pediatr Infect Dis J; 2014 Dec; 33(12):e316-9. PubMed ID: 24983717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of
    Singkham N; Avihingsanon A; Thammajaruk N; Ruxrungtham K; Bunupuradah T; Kiertiburanakul S; Chetchotisakd P; Burger DM; Emery S; Punyawudho B
    Pharmacogenomics; 2019 May; 20(7):517-527. PubMed ID: 31124411
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients.
    Singkham N; Avihingsanon A; Brundage RC; Birnbaum AK; Thammajaruk N; Ruxrungtham K; Bunupuradah T; Kiertiburanakul S; Chetchotisakd P; Punyawudho B;
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):99-108. PubMed ID: 34727835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.